{"product_id":"tirzepatide","title":"Tirzepatide","description":"\u003cmeta charset=\"UTF-8\"\u003e\n\u003cstyle\u003e\n:root{--d:#0b3347;--p:#0e4f68;--m:#2590b4;--l:#5ab4cc;--pl:#cce8f2;--ic:#e8f5fa;--t:#0a1e2c;--mu:#456d80;--r:14px}\n*{box-sizing:border-box}.pg{font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',sans-serif;color:var(--t);max-width:880px;margin:0 auto;padding:0 16px 60px;line-height:1.7}\n.pg h1,.pg h2,.pg h3,.pg p,.pg ul,.pg ol,.pg li,.pg a{margin:0 0 10px;font-size:14px}\n.pg h1{font-size:clamp(20px,4vw,32px);font-weight:900;letter-spacing:-.03em;color:var(--d)}\n.pg h2{font-size:17px;font-weight:800;color:var(--d)}\n.pg h3{font-size:14px;font-weight:700;color:var(--p);margin:14px 0 5px}\n.pg a{color:var(--m);text-decoration:underline}\n.hero{background:linear-gradient(135deg,var(--d) 0%,var(--p) 65%,var(--m) 100%);border-radius:var(--r);padding:34px 26px 30px;margin-bottom:22px;color:#fff;position:relative;overflow:hidden}\n.hero::before{content:'';position:absolute;inset:0;background:url(\"data:image\/svg+xml,%3Csvg width='60' height='60' xmlns='http:\/\/www.w3.org\/2000\/svg'%3E%3Cg fill='%23ffffff' fill-opacity='0.04'%3E%3Cpolygon points='30,5 55,18 55,42 30,55 5,42 5,18'\/%3E%3C\/g%3E%3C\/svg%3E\");pointer-events:none}\n.badge{display:inline-flex;align-items:center;background:rgba(255,255,255,.15);border:1px solid rgba(255,255,255,.25);border-radius:20px;padding:3px 12px;font-size:11px;font-weight:600;letter-spacing:.06em;text-transform:uppercase;margin-bottom:11px;gap:5px}\n.hero h1{color:#fff;font-size:clamp(21px,4.5vw,34px);font-weight:900;letter-spacing:-.03em;margin:0 0 8px}\n.hero p{opacity:.88;font-size:14px;max-width:520px;margin:0 0 12px}\n.hmeta{display:flex;flew-wrap:wrap;gap:9px;font-size:11px;opacity:.75}\n.warn{background:#fffbeb;border:1.5px solid #fcd34d;border-left:5px solid #b45309;border-radius:var(--r);padding:11px 14px;margin-bottom:18px;font-size:12.5px;color:#92400e;line-height:1.6}\n.warn strong{color:#78350f}\n.stats{display:grid;grid-template-columns:repeat(auto-fit,minmax(115px,1fr));gap:8px;margin:10px 0 14px}\n.sc{background:var(--ic);border:1.5px solid var(--pl);border-radius:10px;padding:11px 9px;text-align:center}\n.sv{font-size:22px;font-weight:900;color:var(--p);line-height:1;margin-bottom:3px}\n.sl{font-size:9px;color:var(--mu);font-weight:600;text-transform:uppercase;letter-spacing:.05em}\n.ss{font-size:8.5px;color:var(--mu);margin-top:2px}\n.sec{background:#fff;border:1.5px solid var(--pl);border-radius:var(--r);margin-bottom:11px;box-shadow:0 2px 5px rgba(11,51,71,.05);overflow:hidden}\n.sec details\u003esummary{display:flex;align-items:center;justify-content:space-between;padding:14px 18px;cursor:pointer;user-select:none;list-style:none;gap:8px}\n.sec details\u003esummary::-webkit-details-marker,.sec details\u003esummary::marker{display:none}\n.shd{display:flex;align-items:center;gap:8px}\n.sic{width:30px;height:30px;border-radius:7px;flex-shrink:0;background:var(--ic);display:flex;align-items:center;justify-content:center;font-size:15px}\n.stt{font-size:13.5px;font-weight:700;color:var(--p)}.sub{font-size:10.5px;color:var(--mu);margin-top:1px}\n.sarr{width:17px;height:17px;flex-shrink:0;color:var(--m);transition:transform .25s}\ndetails[open] .sarr{transform:rotate(180deg)}\n.sbd{padding:0 18px 18px}.sdiv{height:1.5px;background:var(--pl);margin:0 18px 14px}\n.chart{background:var(--ic);border:1.5px solid var(--pl);border-radius:10px;padding:14px 11px;margin:10px o;overflow-x:auto}\n.ct{font-size:10px;font-weight:700;color:var(--mu);text-transform:uppercase;letter-spacing:.06em;margin-bottom:9px}\n.cs{font-size:9px;color:var(--mu);margin-top:5px;text-align:right}\n.tbl{width:100%;border-collapse:collapse;font-size:12px;margin:8px 0}\n.tbl th{background:var(--p);color:#fff;padding:7px 9px;text-align:left;font-size:10px;text-transform:uppercase;letter-spacing:.05em}\n.tbl th:first-child{border-radius:5px 0 0 0}.tbl th:last-child{border-radius:0 5px 0 0}\n.tbl td{padding:6px 9px;border-bottom:1px solid var(--pl);font-size:12px}\n.tbl tr:last-child td{border-bottom:none}.tbl tr:nth-child(even) td{background:var(--ic)}\n.tbl .ph{font-weight:600;color:var(--p)}.tbl .mx td{background:#e0f2fe!important;font-weight:700;color:var(--d)}\n.recon{background:linear-gradient(135deg,var(--d),var(--p));border-radius:10px;padding:14px 16px;color:#fff;margin:10px 0}\n.recon h3{color:#fff;margin-top:0;font-size:11.5px;opacity:.85;text-transform:uppercase;letter-spacing:.07em}\n.rf{font-size:17px;font-weight:800;margin:4px 0;letter-spacing:-.01em}.rd{font-size:11.5px;opacity:.8}\n.cta{background:linear-gradient(135deg,var(--p),var(--m));border-radius:var(--r);padding:18px 20px;display:flex;align-items:center;justify-content:space-between;flex-wrap:wrap;gap:10px;margin:16px 0;text-decoration:none!important}\n.cta-t{color:#fff}.cta-t strong{display:block;font-size:14px;font-weight:800;margin-bottom:2px}\n.cta-t span{font-size:12px;opacity:.85}\n.cta-b{background:#fff;color:var(--p);font-weight:800;font-size:12px;border-radius:8px;padding:7px 14px;white-space:nowrap;flex-shrink:0}\n.chip{display:inline-flex;background:var(--ic);border:1px solid var(--pl);border-radius:20px;padding:2px 8px;font-size:10px;color:var(--mu);text-decoration:none;margin:2px}\n.chip:hover{background:var(--pl);color:var(--p)}\n.fn{border-top:2px solid var(--pl);margin-top:28px;padding-top:16px}\n.fn h4{font-size:10px;text-transform:uppercase;letter-spacing:.08em;color:var(--mu);margin:0 0 9px}\n.fnl{list-style:none;padding:0;margin:0}.fnl li{font-size:10.5px;color:var(--mu);margin-bottom:5px;padding-left:18px;position:relative;line-height:1.5}\n.fnl li::before{content:attr(data-n);position:absolute;left:0;font-weight:700;color:var(--m)}\n.fnl a{color:var(--m)}\n@media(max-width:600px){.hero{padding:22px 14px 18px}.sbd{padding:0 10px 14px}.cta{flex-direction:column}.stats{grid-template-columns:repeat(2,1fr)}}\n\u003c\/style\u003e\n\u003cdiv class=\"pg\"\u003e\n\u003cdiv class=\"hero\"\u003e\n\u003cdiv class=\"badge\"\u003e🔬 Research Reference · MVLabs.mx · México · GLP-1\/GIP · Dual Agonist\u003c\/div\u003e\n\u003ch1\u003eTirzepatide\u003c\/h1\u003e\n\u003cp\u003eThe first dual GLP-1\/GIP agonist. SURMOUNT-1 Phase 3 showed up to 22.5% mean weight loss — surpassing any previous weight pharmacotherapy. Available for research in Mexico.\u003c\/p\u003e\n\u003cdiv class=\"hmeta\"\u003e\n\u003cspan\u003e📋 Research only\u003c\/span\u003e\u003cspan\u003e💊 10 mg\/vial\u003c\/span\u003e\u003cspan\u003e⏱ t½ ~5 days\u003c\/span\u003e\u003cspan\u003e🇲🇽 México\u003c\/span\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"warn\"\u003e\n\u003cstrong\u003e⚠ Research Use Only \/ Solo Uso de Investigación.\u003c\/strong\u003e All information is for educational and scientific research only. Not approved for human use by FDA or COFEPRIS. For in-vitro and pre-clinical research only. MVLabs.mx · \u003ca href=\"\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"stats\"\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e22.5%\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eMax weight loss\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eSURMOUNT-1\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e5 days\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eHalf-life\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eOnce weekly\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e15 mg\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003eMax dose\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eWeekly SC\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sc\"\u003e\n\u003cdiv class=\"sv\"\u003e2,539\u003c\/div\u003e\n\u003cdiv class=\"sl\"\u003ePhase 3 N\u003c\/div\u003e\n\u003cdiv class=\"ss\"\u003eSURMOUNT-1\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails open\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e🧬\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eMechanism of Action\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003eGLP-1\/GIP Dual Agonist · SURMOUNT Trials\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cp\u003eTirzepatide is a 39-aa peptide with balanced agonism at GLP-1R and GIPR. GIP co-agonism potentiates GLP-1-mediated satiety while reducing nausea, enabling dose escalation to levels not tolerable with GLP-1 alone. Dual mechanism enhances appetite reduction, insulin sensitivity, and adipose remodeling.\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:5px;flex-wrap:wrap;margin-top:6px\"\u003e\u003ca class=\"chip\" href=\"\/pages\/peptide-calculator\"\u003e🧮 Peptide Calculator\u003c\/a\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e📊\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eClinical Evidence\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003ePublished research data\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cp\u003eSURMOUNT-1 (Jastreboff et al., NEJM 2022): N=2,539, 72 weeks.\u003csup class=\"fn\"\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e15 mg\/week: −22.5% mean weight loss\u003c\/li\u003e\n\u003cli\u003e10 mg: −19.5% · 5 mg: −15.0%\u003c\/li\u003e\n\u003cli\u003eFDA approved as Zepbound® (Nov 2023)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"display:flex;gap:5px;flex-wrap:wrap\"\u003e\u003ca class=\"chip\" href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2206038\" target=\"_blank\"\u003e📄 SURMOUNT-1 NEJM\u003c\/a\u003e\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e📋\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eResearch Dosing Protocol\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003e⚠ Research reference only — not medical advice\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\n\u003cdiv class=\"recon\"\u003e\n\u003ch3\u003eReconstitution\u003c\/h3\u003e\n\u003cdiv class=\"rf\"\u003e10 mg + 2 mL BAC Water = 5 mg\/mL\u003c\/div\u003e\n\u003cdiv class=\"rd\"\u003e1 U-100 = 50 µg · Store 2–8°C · Use within 28 days\u003c\/div\u003e\n\u003c\/div\u003e\n\u003ctable class=\"tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePhase\u003c\/th\u003e\n\u003cth\u003eDose\u003c\/th\u003e\n\u003cth\u003eUnits (U-100)\u003c\/th\u003e\n\u003cth\u003eVolume\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eWeeks 1–4\u003c\/td\u003e\n\u003ctd\u003e2.5 mg\u003c\/td\u003e\n\u003ctd\u003e50 U\u003c\/td\u003e\n\u003ctd\u003e0.50 mL\u003c\/td\u003e\n\u003ctd\u003eStarting\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eWeeks 5–8\u003c\/td\u003e\n\u003ctd\u003e5 mg\u003c\/td\u003e\n\u003ctd\u003e100 U\u003c\/td\u003e\n\u003ctd\u003e1.00 mL\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eWeeks 9–12\u003c\/td\u003e\n\u003ctd\u003e7.5 mg\u003c\/td\u003e\n\u003ctd\u003e150 U*\u003c\/td\u003e\n\u003ctd\u003e1.50 mL*\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd class=\"ph\"\u003eWeeks 13–16\u003c\/td\u003e\n\u003ctd\u003e10 mg\u003c\/td\u003e\n\u003ctd\u003e200 U*\u003c\/td\u003e\n\u003ctd\u003e2.00 mL*\u003c\/td\u003e\n\u003ctd\u003ePer tolerance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr class=\"mx\"\u003e\n\u003ctd class=\"ph\"\u003eWeeks 17+\u003c\/td\u003e\n\u003ctd\u003e15 mg\u003c\/td\u003e\n\u003ctd\u003e300 U*\u003c\/td\u003e\n\u003ctd\u003e3.00 mL*\u003c\/td\u003e\n\u003ctd\u003eMax · *use 3mL syringe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ca class=\"cta\" href=\"\/pages\/peptide-calculator\"\u003e\u003cdiv class=\"cta-t\"\u003e\n\u003cstrong\u003e🧮 MVLabs.mx Peptide Calculator\u003c\/strong\u003e\u003cspan\u003eCalculate exact units \u0026amp; volumes — syringe slider included\u003c\/span\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"cta-b\"\u003eOpen Calculator →\u003c\/div\u003e\u003c\/a\u003e\n\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"sec\"\u003e\u003cdetails\u003e\u003csummary\u003e\u003cdiv class=\"shd\"\u003e\n\u003cdiv class=\"sic\"\u003e⚠️\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdiv class=\"stt\"\u003eSafety Profile\u003c\/div\u003e\n\u003cdiv class=\"sub\"\u003eAdverse event reference\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csvg class=\"sarr\" viewbox=\"0 0 24 24\" fill=\"none\" stroke=\"currentColor\" stroke-width=\"2.5\"\u003e\u003cpath d=\"m6 9 6 6 6-6\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\u003c\/summary\u003e\u003cdiv class=\"sdiv\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"sbd\"\u003e\u003cul\u003e\n\u003cli\u003eNausea (~31%), diarrhea (~23%) — milder than semaglutide due to GIP co-agonism\u003c\/li\u003e\n\u003cli\u003eDiscontinuation: 4.3% at 15mg\u003c\/li\u003e\n\u003cli\u003ePancreatitis: rare; monitor\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/div\u003e\u003c\/details\u003e\u003c\/div\u003e\n\u003cdiv class=\"fn\"\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003col class=\"fnl\"\u003e\u003cli data-n=\"[1]\"\u003eJastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205–216. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa2206038\"\u003eDOI\u003c\/a\u003e\n\u003c\/li\u003e\u003c\/ol\u003e\n\u003cp style=\"font-size:10px;color:var(--mu);margin-top:10px\"\u003e© 2026 MVLabs.mx · Tirzepatide México · Zepbound México investigación · GLP-1 GIP México · \u003ca href=\"\/pages\/peptide-calculator\"\u003ePeptide Calculator\u003c\/a\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MV Labs","offers":[{"title":"Default Title","offer_id":44444429320307,"sku":null,"price":2100.0,"currency_code":"MXN","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0697\/3577\/6371\/files\/Gemini_Generated_Image_fhrvpmfhrvpmfhrv.png?v=1773265090","url":"https:\/\/mvlabs.mx\/products\/tirzepatide","provider":"MV Labs","version":"1.0","type":"link"}